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Opioids are broad spectrum analgesics that are an integral part of the therapeutic
armamentarium to combat pain in the clinical practice. Unfortunately, together with
analgesia, a number of adverse effects can occur such as nausea, vomiting,
constipation, gastrointestinal alterations and cognitive impairments. Naltrexone is a
competitive antagonist of opioid receptors commonly used to treat opioid addiction; its
oral use against agonists side effects is limited by the decrease of opioids-therapeutic
efficacy and own adverse effects. The intranasal delivery of naltrexone could offer a quick
and effective achievement of CNS based on extracellular mechanisms including perineural
and perivascular transport. The aim of the study was to test the efficacy of intranasal low-
dose naltrexone in reducing intraperitoneal morphine and oxycodone side effects in
rodents. In mice, 1 mg naltrexone intranasally administered 30 min before opioids reduced
cognitive impairments and motor alteration induced by 10 mg kg−1 morphine and 60 mg
kg−1 oxycodone in the Passive avoidance and Rota rod tests, respectively. Moreover,
naltrexone rebalanced opioid-induced reduction of the intestinal transit and latency of
feces expulsion as well as food intake inhibition. Importantly, 1 mg naltrexone instillation did
not block analgesia as demonstrated by the Hot plate test. In rats, intranasal naltrexone
counteracted the opioid-induced pica phenomenon related to emesis and increased
water and palatable food intake. The effects were comparable to that achieved by
metoclopramide used as reference drug. Treatments did not influence body weight.
Lastly, the safety of the intranasal delivery has been checked by hematoxylin–eosin
staining that did not show histological alterations of the nasal cavity. In conclusion,
intranasal low-dose naltrexone counteracted morphine and oxycodone induced
gastrointestinal and CNS side effects without impairing opioid analgesia. It is a
candidate to be a valid clinical strategy deserving deep analysis.
Keywords: intranasal delivery, morphine, naltrexone, opioids side effects, oxycodonein.org September 2020 | Volume 11 | Article 5766241
Micheli et al. Naltrexone Counteracts Opioid Side EffectsINTRODUCTION
Opioids are the keystone of moderate to severe pain
management. Currently, statistics show that about 90% of
patients are treated with opioids for chronic pain (Manchikanti
et al., 2005; Trescot et al., 2006), and 90% of patients who rely on
a pain management center are already on opioid therapy
(Manchikanti et al., 2004).
Although some patients can achieve sustained partial pain
relief with opioid therapy without intolerable side effects
(Portenoy, 1996), many patients are not being treated
adequately, for reasons that include concerns about tolerability
as well as addiction issues particularly with strong opioids such
as morphine and oxycodone (Nicholson, 2003). Nausea,
vomiting, and constipation, along with central nervous system
side effects, are the principal reasons for discontinuation of
opioid analgesic treatment (Harris, 2008). Regarding the CNS,
the side effects induced by opioids can be divided into three
groups. Reduction of consciousness, sedation, and sleep
disturbances are symptoms classified as the first group. The
second group includes symptoms such as psychomotor
impairment, delirium, hallucinations, dreams, and nightmares
affecting the thought process and the ability to react with
cognitive impairment. Lastly opioids can exert direct toxic
effects on neurons by evoking myoclonus, hyperalgesia, and
tolerance, thus representing the third group of CNS side effects
(Vella-Brincat and MacLeod, 2007). There is no doubt that
successful opioid therapy requires that the benefits of analgesia
clearly outweigh treatment-related adverse effects. Multiple
approaches have been described to address this problem. The
clinical challenge of choosing the best option is enhanced by the
lack of studies able to compare multiples therapeutic approaches
to manage these problems.
A strategy often used to minimize opioid side effects is the
administration of an opioid antagonist either as a co-formulation
product or as a second stand-alone drug.
Naltrexone, a competitive antagonist of m, k, and g opioid
receptors, was synthesized in 1963 and was approved by the
FDA in 1984 for the management of alcoholism and opioid
addiction (Lee and Elston, 2019). However, the therapeutic
benefits are often hampered by the reduction of opioid-
induced analgesia and by the appearance of the withdrawal
syndrome (Culpepper-Morgan et al., 1992; Liu and Wittbrodt,
2002; Tofil et al., 2006). Moreover, the peripheral antagonist
effects may be limited by the oral administration that fails to
provide a complete protection since the direct action on the
gastro-intestinal tract. The nasal route has received a great deal
of attention in recent years as a convenient and reliable method
for the systemic delivery of drugs with the aim of dosage
reduction and for improving the reaching of target site. Based
on these pieces of evidence, the aim of the present study was to
evaluate the efficacy of the intranasal injection of naltrexone in
reducing the several side effects of morphine and oxycodone
administration in rodents. In particular, the effects on
gastrointestinal and neurological alterations induced by the
two opioids were investigated.Frontiers in Pharmacology | www.frontiersin.org 2MATERIALS AND METHODS
Animals
For all the experiments described below, male Sprague–Dawley
rats and CD-1 mice (Envigo, Varese, Italy) weighing
approximately 220–250 g and 20–25 g respectively at the
beginning of the experimental procedure were used. Animals
were housed in Ce.S.A.L (Centro Stabulazione Animali da
Laboratorio, University of Florence) and used at least one week
after their arrival. Four rats or ten mice were housed per cage
(size 26 × 41 cm2); animals were fed with standard laboratory
diet and tap water ad libitum, kept at 23 ± 1°C with a 12 h light/
dark cycle, light at 7 a.m. All animal manipulations were carried
out according to the Directive 2010/63/EU of the European
parliament and of the European Union council (22 September
2010) on the protection of animals used for scientific purposes.
The ethical policy of the University of Florence complies with the
Guide for the Care and Use of Laboratory Animals of the US
National Institutes of Health (NIH Publication No. 85-23,
revised 1996; University of Florence assurance number: A5278-
01). Formal approval to conduct the experiments described was
obtained from the Italian Ministry of Health (No. 54/2014-B)
and from the Animal Subjects Review Board of the University of
Florence. Experiments involving animals have been reported
according to ARRIVE guidelines (McGrath and Lilley, 2015).
All efforts were made to reduce the number of animals used and
to minimize their suffering.
Preparations of Compounds
Naltrexone was solubilized in sterile saline solution and
intranasally administered. Morphine (6 and 10 mg kg−1;
S.A.L.A.R.S., Como, Italy) and oxycodone (45 and 60 mg kg−1;
Molteni, Florence, Italy) were solubilized in sterile saline solution
and intraperitoneally (i.p.) injected 30 after the administration of
naltrexone. Control animals received an equal volume
of vehicles.
Protocol for Intranasal Administration
According to Chen et al. (2002) mice or rats after being
anesthetized (confirmed by the absence of righting reflex) have
been subjected to inoculation with a micropipette; volume 40 ml
of a solution of naltrexone 1 mg in 10 min respecting a time of
2 min between one nostril and the other (4 min for the
instillation into one nostril, a pause of 2 min and another
instillation of 4 min in the other nostril). Control animals were
inoculated intranasally with 40 ml of saline solution.
Hot Plate Test
The method adopted was described by O’Callaghan and
Holtzman (1975). Mice were placed inside a stainless-steel
container inserted in a precision water bath (KW Mechanical
Workshop, Siena, Italy) which was set thermostatically at 52.5 ±
0.1°C. Reaction times (s) were measured with a stopwatch 30 min
after administration of the analgesic drugs (morphine or
oxycodone). The intranasal administration of naltrexone (1, 3,
and 10 mg) was performed 30 min before the administration ofSeptember 2020 | Volume 11 | Article 576624
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fore or hind paws. Those mice scoring less than 12 s and more
than 18 s in the pretest were rejected (30%). An arbitrary cutoff
time of 45 s was adopted. Control animals were treated
with vehicles
Passive-Avoidance Test
The test was performed according to the step-through method
described by Jarvik and Kopp (1967). The apparatus consists of a
two-compartment acrylic box. Alight compartment is connected
to a darkened one by a guillotine door. Mice, as soon as they
entered into the dark compartment, received a punishing
electrical shock (0.5 mA, 1 s). The latency time for entering
into the dark compartment was measured in the training session
and after 24 h in the retention test. The cut-off for the entry
latency allowed in the retention session was 120 s. The deficit in
passive avoidance performance was expressed as the difference
(in seconds) between retention and training latencies. Naltrexone
was administered 30 min before morphine or oxycodone
injection in the training session,
Rota Rod Test
The apparatus consisted of a base platform and a rotating rod
(30 cm in length divided into five equal sections by six disks)
with a diameter of 3 cm and a non-slippery surface. The rod was
placed at a height of 15 cm from the base. Up to five mice were
tested simultaneously on the apparatus, with a rod-rotating
speed of 16 r.p.m. The motor coordination integrity was
assessed on the basis of the time between the moment when
the animals were placed on the rotating rod and the moment in
which they fall or are removed. The cut-off was 120 s. The
animals were trained for two days to remain on the rod for at
least 120 s (Kuribara et al., 1977). The intranasal administration
of naltrexone (1 mg) was performed 30 min before the
administration of the analgesic drugs. The test was performed
30 min after the administration of morphine or oxycodone.
Evaluation of Intestinal Transit
The experiment has been conducted following the method of
Schulz and colleagues using a meal of coal (Schulz et al., 1979).
To mice fasted for 24 h with free access to water has been
administered by gavage a suspension 1.5 ml of 20% (weight/
volume) of carbon in a solution of gum arabic at 5% (weight/
volume). The mice, 20 min after receiving the charcoal meal,
were sacrificed and the intestine was removed en bloc. The transit
in the small intestine was calculated for each mouse as the ratio
between the distance traversed by the charcoal meal and the total
length of the intestine itself.
Evaluation of Colonic Propulsion
The propulsion of the distal colon has been measured according
to the method described by Raffa (1988). 30 min after the
administration of morphine or oxycodone, a bead of glass
(diameter 5 mm) was inserted in the distal colon of each
mouse at 3 cm from the anus. The parameter taken as
reference was the time taken by each mouse ejecting the bead.Frontiers in Pharmacology | www.frontiersin.org 3A greater colonic propulsion was represented by a reduction of
the time of expulsion.
Evaluation of Food Intake in Mice
A weighed amount of food (standard laboratory pellets) was
given to mice without access to food for 8 h (water was available
ad libitum), and the weight consumed (evaluated as the
difference between the original amount and the food left in the
cage, including spillage) was measured 60 min after the injection
of opioids, 90 min after the administration of naltrexone.
Kaolin Preparation and Intake
Kaolin was prepared according to the methods described by
Mitchell and colleagues (Mitchell et al., 1976; Mitchell et al.,
1977). 99 g of pharmacological grade kaolin (hydrated aluminum
silicate, Fisher Scientific Co., Fair Lawn, NJ) was mixed with 1 g
of acacia (gum arabic, Fisher Scientific Co., Fair Lawn, NJ), i.e., in
a 99:1 ratio, with distilled water to form a thick paste. The paste
was rolled on a stainless steel tray and cut into pieces in a shape
and size similar to that of regular rat chow pellets. The pellets
were placed on steel trays and completely dried at room
temperature for 72 h.
Evaluation of Food, Water and Kaolin
Intake in Rats
In rats, a weighed amount of food (standard laboratory pellets),
water, and kaolin was given to animals, and the weight consumed
(evaluated as the difference between the original amount and the
one left in the cages, including spillage) wasmeasured before and 24,
48, 72, and 96 h after treatments. Metoclopramide (5 mg kg−1), used
as reference drug, was suspended in 1% carboxymethylcellulose
sodium salt and orally (p.o.) administered. Control animals were
treated with vehicles.
Body Weight
Body weight was measured before and 24, 48, 72, and 96 h after
treatments. Metoclopramide (5 mg kg−1, p.o.) was used as
reference drug. Control animals were treated with vehicles.
Histological Analysis
Upon sacrifice, mice were decapitated, and whole heads were
decorticated, fixed by immersion in Immunofix (Bio-Optica,
Milan, Italy) for 24 h, followed by decalcification in Biodec R
demineralizing solution (Bio-Optica), freshly replaced every
2 days, until adequate tissue softening was achieved
(approximately 15 days). Then, the anterior part of the skull
including the nasal cavities was dissected, embedded in paraffin,
and cut transversely in 6 µm-thick sections, which were stained
with hematoxylin and eosin (Feldman and Wolfe, 2014).
Statistical Analysis
Statistical analysis results were expressed as means ± S.E.M of 10
animals per group, performed in two different experimental sets.
The analysis of variance was performed by one-way ANOVA. A
Bonferroni’s significant difference procedure was used as post-
hoc comparison. P values of less than 0.05, 0.01, or 0.001 wereSeptember 2020 | Volume 11 | Article 576624
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9.1” software.RESULTS
Before proceeding with the evaluation of the efficacy of
naltrexone in reducing the side effects of morphine and
oxycodone, we first individuated the dose of the opioid
antagonist that did not interfere with the analgesic effect of the
drugs. Naltrexone (1, 3, or 10 mg) was intranasally administered
30 min before morphine (6–10 mg kg−1) or oxycodone (45–60
mg kg−1); the dose of 1 mg did not reduce the opioid’s analgesia in
the mouse Hot plate test, while the higher doses significantly
lowered the licking latency time of the mice with respect to the
animals treated vehicle (Figure 1). Based on these pieces of
evidences, during the following tests the dose of naltrexone used
was 1 mg/mouse. Intranasal pre-treatment with naltrexone was
challenged in reducing the amnesic effect of morphine and
oxycodone in the Passive avoidance test (Figure 2). 1 mg
naltrexone, when administered 30 min before the injection of
morphine, was able to significantly antagonize the cognitive
deficit induced by morphine at the dose of 10 mg kg 10 mg
kg-1 i.p. No efficacy was recorded for the lower dose of morphine
(Figure 2A).Frontiers in Pharmacology | www.frontiersin.org 4Similarly to what was seen for morphine, also the amnesia
induced by oxycodone (60 mg kg−1 i.p.) in the mouse Passive
avoidance test was reduced in a statistically significant manner
by the pre-treatment with naltrexone. On the contrary, the
amnesia induced in the same test by oxycodone, at the dose of
45 mg kg−1 i.p., was not changed by the administration of
naltrexone (Figure 2B). Naltrexone administered alone at all
times taken into consideration had no effect in the mice Passive
avoidance test (Figure 2). None of the tested compounds exerts
any effect on training latency (Data not shown).
The reduction of the endurance time exerted by the opioids in
a dose-dependent manner in the Rota rod test was counteracted
by pre-treatment with naltrexone in both groups treated with 10
mg kg−1 morphine or 60 mg kg−1 oxycodone (Figure 3).
It’s well known that opioids also caused gastrointestinal side
effects like nausea and vomiting, decrease of appetite and reduction
of intestinal transit. In Figure 4 is represented the antagonism
exerted by 1 mg naltrexone on the inhibition of the intestinal
peristalsis induced by 10 mg kg−1 morphine and 60 mg kg−1
oxycodone. Naltrexone, administered 30 min before the opioids,
significantly increased the intestinal transit in both groups.
Moreover, the higher doses of morphine and oxycodone reduced
in mice the colonic propulsion evaluated as the time necessary for
the animal to expel the glass bead insert into the distal colon.
Similarly to previous results, pre-treatment with naltrexoneA B
D E F
C
FIGURE 1 | Effect of intranasal administration of naltrexone on morphine and oxycodone analgesia. The response to a thermal non noxious stimulus was evaluating
by measuring the licking latency (s) as a pain related behaviour by the Hot plate test. Naltrexone (1, 3 and 10 mg) was intranasally administered 30 min before the
intraperitoneal injection of (A–C) morphine (6 and 10 mg kg-1) or (D–F) oxycodone (45 and 60 mg kg-1). Behavioural measurements were performed 30 min after
opioids treatment. Control animals were treated with vehicles. Each value represents the mean of 10 mice per group, performed in two different experimental set.
**P < 0.01 vs vehicle-treated animals; ^^P < 0.01 vs morphine or oxycodone- treated animals.September 2020 | Volume 11 | Article 576624
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latency of expulsion (Figure 5). No effects were recorded when
naltrexone was administered alone. Both morphine and oxycodone
significantly decreased in a dose-dependent manner the food intake
in 8 h food deprived mice (Figure 6). The anorectic activity
exhibited by the two opioid agonists at the dose respectively of
10 and 60 mg kg−1 was reverted by 1 mg naltrexone given 30 min
before (Figure 6).
The next step of the study was to evaluate the effects of
intranasal microdoses of naltrexone in preventing emesis
induced by morphine and oxycodone in rats.
Emesis was evaluated measuring the characteristic increased
consumption of a non-palatable food, a behavior termed “pica”.
Kaolin intake as well as food consumption, water intake, and
body weight were evaluated 24, 48, 72, and 96 h after treatment.
Metoclopramide (5 mg kg−1 p.o.) was used as reference drug.
As shown in Figure 7, both doses of morphine induced the
pica phenomenon related to emesis. Kaolin intake was increasedFrontiers in Pharmacology | www.frontiersin.org 5by morphine from 24 to 72 h after administration. A single
intranasal dose of naltrexone significantly reduced kaolin intake
at all time points. Metoclopramide is a little more efficient
without reaching the values of control animals. Similarly,
naltrexone prevented the kaolin intake increase induced by
oxycodone peaking between 24 and 48 h. Naltrexone and
metoclopramide per se did not induce effects.
As previously reported, opioid induced also a decrease of food
consumption evaluated at the same time points after treatment
(Figure 8). The effects of morphine and oxycodone were
significant after 24 and 48 h. Naltrexone strongly reduced this
effect of opioid agonists; in particular, it fully blocked both
morphine and oxycodone when dosed at 6 and 45 mg kg−1,
respectively. Similarly, the water intake was also altered by the
emetic properties of opioid agonists (Figure 8). This effect was
selectively recorded 24 h after the administration of both
morphine and oxycodone. Naltrexone significantly preventedA
B
FIGURE 2 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced amnesia in the mouse. Memory impairment was
evaluated by the Passive avoidance test. Naltrexone 1 mg was intranasally
administered 30 min before the intraperitoneal injection of (A) morphine
(6 and 10 mg kg−1) or (B) oxycodone (45 and 60 mg kg−1). Behavioral
measurements were performed 30 min after opioid treatment. Control animals
were treated with vehicles. Each value represents the mean of 10 mice per
group, performed in two different experimental sets. *P < 0.05 and **P < 0.01
vs vehicle-treated animals; ^P < 0.05 vs morphine or oxycodone-treated animals.A
B
FIGURE 3 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced motor incoordination in the mouse. Motor impairment
was evaluated by the Rota rod test. Naltrexone 1 mg was intranasally
administered 30 min before the intraperitoneal injection of (A) morphine
(6 and 10 mg kg−1) or (B) oxycodone (45 and 60 mg kg−1). Behavioral
measurements were performed 30 min after opioid treatment. Control animals
were treated with vehicles. Each value represents the mean of 10 mice per
group, performed in two different experimental sets. *P < 0.05 and **P < 0.01
vs vehicle-treated animals; ^P < 0.05 and ^^P < 0.0 vs morphine or
oxycodone-treated animals.September 2020 | Volume 11 | Article 576624
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oxycodone 45 mg kg−1 when antagonism allowed for
maintaining the values of the control animals. The animal’s
body weight was also measured over time remaining unaltered in
comparison to controls (Supplementary Figure 1). Naltrexone
and metoclopramide per se did not induce effects in food
consumption, water intake, and body weight.
Finally, the safety of the intranasal injection of naltrexone was
evaluated by a histological analysis of the nasal cavity 24 h after
the administration of 1 µg/mouse. As shown in Figure 9, no
histological differences were observed between the naltrexone-
treated and the vehicle-treated animals. In particular, in both
animal groups, the septal and lateral mucosa showed normally
appearing ciliated columnar epithelium, muciparous glands and
stroma; no signs of mucus hyper-production and secretion were
detected in the nasal cavities.Frontiers in Pharmacology | www.frontiersin.org 6DISCUSSION
Our study highlighted the efficacy of the intranasal treatment
with low-dose naltrexone in reducing morphine and oxycodone
side effects. In particular, we demonstrated that naltrexone,
intranasally administered, can attenuate gastrointestinal and
neurological adverse reactions induced by the administration
of the opioids and the efficaciousness of the antagonism used did
not impair the analgesic effect of morphine and oxycodone.
The crucial location of pain control is in the CNS. The three
major classes of opioid receptors, m, k, and d are situated
throughout the CNS and the periphery. However, the major
receptor involved in pain modulation is the m-opioid receptor
(Shook et al., 1987).
Despite the fact that the analgesics used for pain control
remain selective for the m-receptor at normal therapeutic doses,A
B
FIGURE 4 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced inhibition of intestinal peristalsis in the mouse. Intestinal
transit was expressed as the ratio between the distance traversed by the
charcoal meal and the total length of the intestine itself. Naltrexone 1 mg was
intranasally administered 30 min before the intraperitoneal injection of
(A) morphine (6 and 10 mg kg−1) or (B) oxycodone (45 and 60 mg kg−1).
Behavioral measurements were performed 30 min after opioid treatment.
Control animals were treated with vehicles. Each value represents the mean
of 10 mice per group, performed in two different experimental sets. *P < 0.05
and **P < 0.01 vs vehicle-treated animals; ^^P < 0.01 vs morphine or
oxycodone-treated animals.A
B
FIGURE 5 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced inhibition of colonic propulsion in the mouse. The
propulsion of the distal colon was evaluated by inserting a bead of glass in
the distal colon of each animal 30 min after the administration of (A) morphine
10 mg kg−1 or (B) oxycodone 60 mg kg−1. Naltrexone 1 mg was intranasally
administered 30 min before the intraperitoneal injection of the opioids. Control
animals were treated with vehicles. Each value represents the mean of 10
mice per group, performed in two different experimental sets. **P < 0.01 vs
vehicle-treated animals; ^P < 0.05 vs morphine or oxycodone-treated
animals.September 2020 | Volume 11 | Article 576624
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before, in the clinical practice, it is required to maintain opioid
analgesia and avoid or minimize the collateral effects that are
commonly gastrointestinal and/or neurological. A condition
termed “poor responsiveness” is reached when a favorable
balance between analgesia and collateral effects cannot
be achieved.
Naltrexone, FDA approved for both alcohol and opioid use
disorders, is a competitive opioid antagonist with a very high
binding affinity for m-opioid receptors (Heading, 2006; Sudakin,
2016). Like other tertiary opioid receptor antagonists, naltrexone
is quite lipid soluble and readily crosses the blood brain barrier. It
is important to say that this non-selective antagonist block all
effects of opioid drugs, including centrally mediated pain relief. A
selective antagonism of the effects of opioids on the gut has beenA
B
FIGURE 6 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced food intake inhibition in the mouse. Food consumption
was expressed as the weight consumed (mg/mouse) during 60 min after the
injection of (A) morphine (6–10 mg kg−1) or (B) oxycodone (45–60 mg kg−1).
Naltrexone 1 mg was intranasally administered 30 min before the
intraperitoneal injection of the opioids. Control animals were treated with
vehicles. Each value represents the mean of 10 mice per group, performed in
two different experimental sets. *P < 0.05 and **P < 0.01 vs vehicle-treated
animals; ^^P < 0.01 vs morphine or oxycodone-treated animals.Frontiers in Pharmacology | www.frontiersin.org 7A
B
C
FIGURE 7 | Effect of intranasal administration of naltrexone on morphine and
oxycodone induced “pika” phenomenon in the rat. Nausea/emesis related to
opioids was evaluated as the increased of the kaolin intake expressed in
grams 60 min after the administration of (A) metoclopramide (5 mg kg−1) or
naltrexone 1 mg, (B) morphine (6–10 mg kg−1) and (C) oxycodone (45–60 mg
kg−1) with the pretreatment with naltrexone 1 mg 30 min before the opioids.
Control animals were treated with vehicles. Each value represents the mean
of 10 rats per group, performed in two different experimental sets. *P < 0.05
and **P < 0.01 vs vehicle-treated animals; ^P < 0.05 and ^^P < 0.01 vs
morphine or oxycodone-treated animals.September 2020 | Volume 11 | Article 576624
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FIGURE 8 | Effect of intranasal administration of naltrexone on morphine and oxycodone reduced food and water intake in the rat. (A–C) Water and food (D–F)
intake were measured up to 96 h after morphine (6–10 mg kg−1) or oxycodone (45–60 mg kg−1) administration. Metoclopramide (5 mg kg−1) or naltrexone (1 mg)
was administered 30 min before the opioids. Control animals were treated with vehicles. Each value represents the mean of 10 rats per group, performed in two
different experimental sets. *P < 0.05 and **P < 0.01 vs vehicle-treated animals; ^P < 0.05 and ^^P < 0.01 vs morphine or oxycodone-treated animals.A
B
FIGURE 9 | Effect of intranasal administration of naltrexone on mouse nasal cavity. Histological analysis of hematoxylin-and-eosin (HE)-stained cross-sections of
whole specimens taken from mice given nasal instillations of (A) vehicle or (B) naltrexone 24 h before. Septal mucosa, including ciliated surface epithelium,
muciparous glands, and stroma, shows a normal appearance in both experimental groups that were analyzed. Images are representative of at least four animals
from two independent experiments.Frontiers in Pharmacology | www.frontiersin.org September 2020 | Volume 11 | Article 5766248
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reducing opioid-induced collateral effects has been limited by
the likelihood of the antagonists to reverse analgesia or to induce
opioid withdrawal (Culpepper-Morgan et al., 1992; Cheskin
et al., 1995).
Moreover, the oral administration of naltrexone is not free
from its own gastrointestinal symptoms, particularly nausea and
vomiting. Other effects are reported such as headaches, skin
rashes, decreased mental acuity, depression, anxiety, and loss of
energy (Gonzalez and Brogden, 1988). Preclinical studies
demonstrated that adding ultra-low doses of oral opioid
receptor antagonists (e.g., naltrexone or naloxone) to opioids
can selectively block the sensitive excitatory mechanism,
unveiling a potent inhibitory process and suppressing the
associated possible opioid side effects (Crain and Shen, 2000). In
human, however, this strategy to add low doses of naloxone (0.6
mg/ml) to morphine in patient-controlled analgesia programs has
failed to improve the analgesic properties of the drug and to
reduce the opioid side effects (Cepeda et al., 2004). On the other
hand, increasing the dose of antagonist reduced the therapeutic
benefits of opioids. For these reasons, investigating an alternative
but still valuable route to administer naltrexone is a clear necessity.
Since the eighties, intranasal drug administration has gained a
growing interest. The intranasal route of administration is
characterized to be non-invasive and suitable for a local,
systemic, and CNS action. Although, the nasal epithelium
appears as a tight barrier, the tightness of the intercellular
junctional complex of the nasal mucosa is low due to leaky
epithelial tissue, and compared to other mucosae, it is easily
accessible (Wolburg et al., 2008; Deli, 2009). In addition, an
optimal absorption surface for the drug delivery is provided by
the extensive vascularization of the mucosa and the lamina
propria (Wengst and Reichl, 2010; Lungare et al., 2016). As
mentioned before, the nasal route shows several advantages in
comparison to the oral or intravenous administration. It is
essentially painless, allows a rapid onset of the therapeutic
effect and a higher drug bioavailability due to avoidance of
hepatic first-pass metabolism. Moreover, bypassing the BBB,
the availability of the drug may potentially increase in the
central nervous system (CNS) (Dufes et al., 2003). Furthermore,
this route of administration allows for lowering the dosages of the
drugs thus reducing their side effects. In this study we firstly
evaluated if the intranasal administration of naltrexone could alter
the analgesic properties of morphine and oxycodone, and we
therefore individuated the dose, 1 mg, that did not interfere with
opioid’s analgesia and that was used for all the experiments.
Sedation and decreased cognition are examples of CNS
adverse effects associated with opioid use. Commonly they are
transient, although some patients require additional therapy to
avoid these unwanted effects. Studies have explored various long-
term effects of exposure to opioids, and it has been demonstrated
that opioid addiction causes disturbances in mood and promotes
anxiety, depression, and cognitive impairments (Compton III
and Wilson, 2000; Swendsen, 2000).
Nevertheless, the impairment by acute morphine in memory
retrieval is also reported. In preclinical evaluations, the effectFrontiers in Pharmacology | www.frontiersin.org 9generated was compared to that induced by scopolamine,
suggesting that morphine-induced memory impairment
resembles scopolamine-induced deficits (El-Sherbiny et al.,
2003). We reproduced in mice memory impairments induced
by the acute injection of the opioids, evaluated by the Passive
avoidance challenge, and pre-treatment with intranasal naltrexone,
30 min before morphine or oxycodone administration, was able to
rebalance the alterations. Moreover, naltrexone was also active in
counteracting opioid-induced motor dysfunctions. These results
are promising since a recent systematic review highlighted that yet
today the effectiveness of opioid antagonists to reduce opioid side
effect is still debated, in particular, for the lack of research
evaluating potential differences in functional effects among
medication types, the route of administration, treatment
modality, and length of treatment (Maglione et al., 2020).
Moving to the gastrointestinal problems, although the
constipation represents the most common adverse event of long
term opioid therapy (40–95%), the adverse events on the GI
system result in a more generalized condition called the opioid
induced bowel dysfunction (OIBD) (Swegle and Logemann, 2006;
Benyamin et al., 2008; Bell et al., 2009). A constellation of
symptoms embraces the manifestation of OIBD, like dry mouth,
vomiting, bloating abdominal pain, anorexia, gastro-esophageal
reflux, hard dry stool, straining to pass bowel movements, and
incomplete evacuation (Bell et al., 2009; Brock et al., 2012).
The innervation of the GI system is comprised of two main
parts; the enteric nervous system (ENS)— the “brain” of the gut,
controlled and regulated by two major plexuses: the myenteric
plexus (which controls intestinal motor activity) and the
submucosal plexus (which controls secretory and absorptive
activity) and the visceral afferents, mediating conscious
sensation together with autonomous system nerves to the CNS
(Brock et al., 2012). The opioid-induced alterations of the GI
tract motility are due to the activation of the opioid receptors that
lead to the inhibition of the secretion of several neurotransmitters
(Wood and Galligan, 2004). As mentioned before, the most
common non-transient side effect of opioids is constipation
(Pappagallo, 2001). Opioid-induced constipation is caused by
the reduction of the peristaltic movements by the binding of
opioids on the m-receptor in the intestines (De Luca and Coupar,
1996) and normally is managed with fibers, linaclotide, and
prucalopride, the common treatments used for functional
constipation. Recently, specific oral treatments with antagonists
directed to the opioid m receptor in the GI tract (PAMORAs) have
been made available (e.g. naloxegol, naldemedine) (Corsetti and
Tack, 2015a; Corsetti and Tack, 2015b). However, surveys have
shown that only 46% of patients with constipation originated
from opioids achieve desired treatment results >50% of the time
(Pappagallo, 2001). A preclinical study also demonstrated that
when naldemedine is orally used in a range dose from 10 to 30
mg/kg, a significant delayed reduction of the analgesic effect of
morphine was recorded (Kanemasa et al., 2019). Intestinal transit
and motility were analyzed in this study after the intraperitoneal
injection of morphine and oxycodone, and both were able to alter
these parameters at the higher dose tested. Also in these
challenges, pre-treatment with intranasal administration ofSeptember 2020 | Volume 11 | Article 576624
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effects, confirming the efficacy of the intranasal route. The validity
of naltrexone against morphine-induced gastrointestinal disorders
was previously studied by Webster and colleagues with an open-
label study assessing a 12-month safety of a combination of
extended-release pellets of morphine sulfate with a sequestered
naltrexone core in patients with chronic, moderate to severe pain
(Webster et al., 2010).
Of 465 patients receiving one or more doses, 81.3 of patients
experienced one or more adverse events, most commonly
constipation (31.8%) or nausea (25.2%) assuming that the
formulation does not resolve opiate bowel dysfunction or
constipation (Webster et al., 2010). Nevertheless, a study
conducted by Raffaeli and colleagues demonstrated the efficacy
of low-dose naltrexone to prevent several side effects in patients
with cancer pain treated with morphine (Raffaeli and Indovina,
2015). However, despite the theoretical basis and the potential
advantages of the use of a single opioid antagonist at low doses,
so far this approach has not been intensively pursued and needs
to be deeply investigated.
Lastly, we evaluated emesis as another common side effect of
opioid therapy (Borison and Wang, 1953). This symptom occurs
in about one-third of patients treated with morphine, and the
incidence severity is roughly in the same ballpark for all opioids
(Lehmann, 1997).
The experience of nausea/vomiting may involve multiple
receptors (Smith, 2005). Opioid-induced nausea/vomiting
(OINV) has not been extensively studied because it is difficult
to discriminate it from radiation-induced emesis, chemotherapy-
induced nausea/vomiting, or postoperative nausea/vomiting.
Despite the fact that the precise mechanisms of OINV are not
entirely clear, it can be supposed that multiple and complex tools
are implicated including the enhancement of the vestibular
sensitivity, a direct effect on the chemoreceptor trigger zone
and a delay of gastric emptying. We evaluated emesis in rats
measuring the characteristic increased consumption of non-
nutritive substances, a behavior termed “pica” (Mitchell et al.,
1976) after morphine and oxycodone administration. Kaolin
consumption increased, while decreased normal food and
water intakes were restored by intranasal pretreatment with
naltrexone. Despite the reduction of palatable food intake, the
body weight of the animals wasn’t changed by the treatment
used. Most probably no effects on weight animals were recorded
since we evaluated the effects only up to 96 h after treatments.
Lastly, a histological evaluation of the nasal cavity of the
animals 24 h after the administration of naltrexone was conducted to
validate the safety of the route of administration. No histologicalFrontiers in Pharmacology | www.frontiersin.org 10alterations were highlighted on naltrexone-treated animals in
comparison to the control group underling the safety of the treatment.CONCLUSION
In conclusion, intranasal low-dose naltrexone was able to
counteract morphine and oxycodone induced gastrointestinal
and CNS side effects with no action on opioid’s analgesia. These
promising results require further in-depth studies for a possible
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